Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation
- PMID: 22364599
- DOI: 10.1111/j.1464-5491.2012.03617.x
Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation
Abstract
New-onset diabetes after transplantation is recognized as one of the metabolic consequences which may increase the risk of morbidity and mortality after solid organ transplantation. The pathophysiology of new-onset diabetes after transplantation has not been clearly defined and may resemble that of Type 2 diabetes, characterized by predominantly insulin resistance or defective insulin secretion, or both. This review aims to summarize the current state of knowledge regarding the prevalence, consequences, pathogenesis, and management of new-onset diabetes after transplantation, with a major focus on the possible mechanisms involved in the pathogenesis of the disorder. The aetiology of new-onset diabetes after transplantation is multifactorial, with diabetogenic immunosuppressive drugs playing a major role. Multiple cellular and physiologic mechanisms are involved in the process. Selection of an appropriate maintenance immunosuppressive regimen should involve balancing the risk of patient and graft survival vs. the potential for new-onset diabetes after transplantation.
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.
Similar articles
-
New-onset diabetes mellitus after solid organ transplantation.Transpl Int. 2009 May;22(5):519-30. doi: 10.1111/j.1432-2277.2008.00800.x. Epub 2008 Nov 20. Transpl Int. 2009. PMID: 19040489 Review.
-
New-onset diabetes after transplantation.J Heart Lung Transplant. 2004 May;23(5 Suppl):S194-201. doi: 10.1016/j.healun.2004.03.007. J Heart Lung Transplant. 2004. PMID: 15093805 Review.
-
Predicting, managing and preventing new-onset diabetes after transplantation.Minerva Endocrinol. 2012 Sep;37(3):233-46. Minerva Endocrinol. 2012. PMID: 22766890 Review.
-
New-onset diabetes after transplantation: risk factors and clinical impact.Diabetes Metab. 2011 Feb;37(1):1-14. doi: 10.1016/j.diabet.2010.09.003. Epub 2011 Feb 3. Diabetes Metab. 2011. PMID: 21295510 Review.
-
The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus.Pediatr Diabetes. 2012 Feb;13(1):81-91. doi: 10.1111/j.1399-5448.2011.00782.x. Epub 2011 May 19. Pediatr Diabetes. 2012. PMID: 21595806 Review.
Cited by
-
The case for the therapeutic use of mechanistic/mammalian target of rapamycin (mTOR) inhibitors in xenotransplantation.Xenotransplantation. 2023 May-Jun;30(3):e12802. doi: 10.1111/xen.12802. Epub 2023 Apr 7. Xenotransplantation. 2023. PMID: 37029499 Free PMC article. Review.
-
Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure.Front Clin Diabetes Healthc. 2021 Aug 23;2:731574. doi: 10.3389/fcdhc.2021.731574. eCollection 2021. Front Clin Diabetes Healthc. 2021. PMID: 36994340 Free PMC article. Review.
-
Management and Risks Before, During, and After Liver Transplant in Individuals With Obesity.Gastroenterol Hepatol (N Y). 2023 Jan;19(1):20-29. Gastroenterol Hepatol (N Y). 2023. PMID: 36865816 Free PMC article.
-
Incidence, Risk Factors and Clinical Implications of Glucose Metabolic Changes after Heart Transplant.Biomedicines. 2022 Oct 26;10(11):2704. doi: 10.3390/biomedicines10112704. Biomedicines. 2022. PMID: 36359224 Free PMC article.
-
A retrospective cohort study of preoperative lipid indices and their impact on new-onset diabetes after liver transplantation.J Clin Lab Anal. 2020 May;34(5):e23192. doi: 10.1002/jcla.23192. Epub 2020 Jan 24. J Clin Lab Anal. 2020. PMID: 31981248 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
